“This funding does not result in any change to Moderna's 2024 research and development framework of approximately $4.5 billion.” Moderna CEO Stéphane ... COVID and flu vaccine, dubbed MRNA ...
News that the Biden administration is planning to push for Americans to get the updated COVID vaccines this fall caused several vaccine manufacturers' stock prices to rise Monday. Moderna CEO ...
Moderna Inc. announced Tuesday that its next-generation COVID vaccine produced better immune results in a late-stage trial than its previous vaccines, and will be a key part of its combination ...
It also had plans to start filling doses of its COVID vaccine in the continent as early as 2023. However, Moderna has not received ... on the back of a plunge in prices for rare earths but ...
Moderna (NASDAQ:MRNA) is obviously best known as a vaccine company, with much of its success in recent years owed to their COVID-19 vaccines. Of course, this isn't the only story they're working ...
Moderna (MRNA) is advancing three of its vaccines into Phase Three trials as the pharmaceutical giant hopes to expand its product pipeline past its COVID-19 vaccine, sales of which fell by 43% ...
Covid vaccines from companies like Pfizer, Moderna and AstraZeneca were linked to rare occurrences of heart, brain and blood ...
Authors focused their research on those who received the COVID vaccine from Pfizer or Moderna and died within 100 days of receiving their shots. Only 40 deaths occurred in that window. Of the 40 ...
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. US biotech Moderna has put plans to build a vaccine plant in Kenya on hold, in a sign that moves to invest ...
CAMBRIDGE, MA / ACCESSWIRE / March 26, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that mRNA-1283, the Company's next-generation COVID-19 vaccine, has successfully met the primary endpoints ...